ACVRL1

Protein-coding gene in humans
ACVRL1
Available structures
PDBOrtholog search: PDBe RCSB
List of PDB id codes

2LCR, 3MY0, 4FAO

Identifiers
AliasesACVRL1, ACVRLK1, ALK-1, ALK1, HHT, HHT2, ORW2, SKR3, TSR-I, activin A receptor like type 1
External IDsOMIM: 601284 MGI: 1338946 HomoloGene: 20058 GeneCards: ACVRL1
Gene location (Human)
Chromosome 12 (human)
Chr.Chromosome 12 (human)[1]
Chromosome 12 (human)
Genomic location for ACVRL1
Genomic location for ACVRL1
Band12q13.13Start51,906,908 bp[1]
End51,923,361 bp[1]
Gene location (Mouse)
Chromosome 15 (mouse)
Chr.Chromosome 15 (mouse)[2]
Chromosome 15 (mouse)
Genomic location for ACVRL1
Genomic location for ACVRL1
Band15|15 F1Start101,026,403 bp[2]
End101,043,217 bp[2]
RNA expression pattern
Bgee
HumanMouse (ortholog)
Top expressed in
  • right lung

  • upper lobe of left lung

  • left uterine tube

  • lower lobe of lung

  • right lobe of thyroid gland

  • subcutaneous adipose tissue

  • canal of the cervix

  • rectum

  • left lobe of thyroid gland

  • left ventricle
Top expressed in
  • right lung

  • left lung

  • right lung lobe

  • left lung lobe

  • extensor digitorum longus muscle

  • extraocular muscle

  • plantaris muscle

  • lip

  • yolk sac

  • ankle joint
More reference expression data
BioGPS
More reference expression data
Gene ontology
Molecular function
  • transferase activity
  • nucleotide binding
  • protein kinase activity
  • activin binding
  • transforming growth factor beta-activated receptor activity
  • metal ion binding
  • kinase activity
  • protein serine/threonine kinase activity
  • transmembrane receptor protein serine/threonine kinase activity
  • protein binding
  • BMP receptor activity
  • ATP binding
  • protein kinase binding
  • transforming growth factor beta binding
  • transforming growth factor beta receptor activity, type I
  • activin receptor activity, type I
  • SMAD binding
  • growth factor binding
Cellular component
  • integral component of membrane
  • membrane
  • integral component of plasma membrane
  • neuronal cell body
  • dendrite
  • plasma membrane
  • cell surface
  • receptor complex
  • activin receptor complex
Biological process
  • cellular response to transforming growth factor beta stimulus
  • negative regulation of cell adhesion
  • regulation of transcription, DNA-templated
  • positive regulation of endothelial cell differentiation
  • positive regulation of endothelial cell proliferation
  • blood vessel morphogenesis
  • negative regulation of blood vessel endothelial cell migration
  • lymphangiogenesis
  • regulation of DNA replication
  • phosphorylation
  • endothelial tube morphogenesis
  • retina vasculature development in camera-type eye
  • wound healing, spreading of epidermal cells
  • lymphatic endothelial cell differentiation
  • positive regulation of pathway-restricted SMAD protein phosphorylation
  • cellular response to BMP stimulus
  • negative regulation of endothelial cell differentiation
  • in utero embryonic development
  • blood vessel endothelial cell proliferation involved in sprouting angiogenesis
  • blood circulation
  • positive regulation of angiogenesis
  • venous blood vessel development
  • negative regulation of endothelial cell migration
  • negative regulation of endothelial cell proliferation
  • regulation of blood vessel endothelial cell migration
  • regulation of blood pressure
  • positive regulation of transcription, DNA-templated
  • protein phosphorylation
  • blood vessel remodeling
  • negative regulation of cell migration
  • transmembrane receptor protein serine/threonine kinase signaling pathway
  • negative regulation of cell growth
  • positive regulation of chondrocyte differentiation
  • angiogenesis
  • artery development
  • regulation of endothelial cell proliferation
  • positive regulation of BMP signaling pathway
  • transforming growth factor beta receptor signaling pathway
  • negative regulation of focal adhesion assembly
  • negative regulation of DNA biosynthetic process
  • signal transduction
  • negative regulation of cell population proliferation
  • blood vessel maturation
  • activin receptor signaling pathway
  • response to hypoxia
  • endocardial cushion to mesenchymal transition
  • endocardial cushion morphogenesis
  • negative regulation of gene expression
  • dorsal aorta morphogenesis
  • positive regulation of transcription by RNA polymerase II
  • BMP signaling pathway
  • pattern specification process
Sources:Amigo / QuickGO
Orthologs
SpeciesHumanMouse
Entrez

94

11482

Ensembl

ENSG00000139567

ENSMUSG00000000530

UniProt

P37023

Q61288

RefSeq (mRNA)

NM_000020
NM_001077401

NM_001277255
NM_001277257
NM_001277258
NM_001277259
NM_009612

RefSeq (protein)

NP_000011
NP_001070869

NP_001264184
NP_001264186
NP_001264187
NP_001264188
NP_033742

Location (UCSC)Chr 12: 51.91 – 51.92 MbChr 15: 101.03 – 101.04 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Serine/threonine-protein kinase receptor R3 is an enzyme that in humans is encoded by the ACVRL1 gene.[5][6][7]

ACVRL1 is a receptor in the TGF beta signaling pathway. It is also known as activin receptor-like kinase 1, or ALK1.

Function

This gene encodes a type I cell-surface receptor for the TGF-beta superfamily of ligands. It shares with other type I receptors a high degree of similarity in serine-threonine kinase subdomains, a glycine- and serine-rich region (called the GS domain) preceding the kinase domain, and a short C-terminal tail. The encoded protein, sometimes termed ALK1, shares similar domain structures with other closely related ALK or activin receptor-like kinase proteins that form a subfamily of receptor serine/threonine kinases. Mutations in this gene are associated with hereditary hemorrhagic telangiectasia (HHT) type 2, also known as Rendu-Osler-Weber syndrome 2.[7]

Pathology

Germline mutations of ACVRL1 are associated with:

Somatic mosaicism in ACVRL1 are associated with severe pulmonary arterial hypertension.[10]

ACVRL1 directly interacts with low-density lipoprotein (LDL), which implies that it might initiate the early phases of atherosclerosis.[11]

Abnormal activity of ACVRL1 has been found to be closely associated with idiopathic pulmonary arterial hypertension.

As a drug target

  • Dalantercept is an experimental ALK1 inhibitor.[12]

Closely/family related kinases

(Not to be confused with anaplastic lymphoma kinase (ALK) )
ALK4 is ACVR1B, ALK7 is ACVR1C, and ALK5 is [part of] the TGF-β type I receptor.[13]

See also

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000139567 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000000530 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ ten Dijke P, Ichijo H, Franzén P, Schulz P, Saras J, Toyoshima H, Heldin CH, Miyazono K (October 1993). "Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity". Oncogene. 8 (10): 2879–87. PMID 8397373.
  6. ^ Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, Guttmacher AE, Jackson CE, Attisano L, Kucherlapati R, Porteous ME, Marchuk DA (June 1996). "Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2". Nature Genetics. 13 (2): 189–95. doi:10.1038/ng0696-189. PMID 8640225. S2CID 21379604.
  7. ^ a b "Entrez Gene: ACVRL1 activin A receptor type II-like 1".
  8. ^ Olivieri C, Mira E, Delù G, Pagella F, Zambelli A, Malvezzi L, Buscarini E, Danesino C (July 2002). "Identification of 13 new mutations in the ACVRL1 gene in a group of 52 unselected Italian patients affected by hereditary haemorrhagic telangiectasia". Journal of Medical Genetics. 39 (7): 39e–39. doi:10.1136/jmg.39.7.e39. PMC 1735165. PMID 12114496.
  9. ^ Vandenbriele C, Peerlinck K, de Ravel T, Verhamme P, Vanassche T (April 2014). "Pulmonary arterio-venous malformations in a patient with a novel mutation in exon 10 of the ACVRL1 gene". Acta Clinica Belgica. 69 (2): 139–41. doi:10.1179/0001551213Z.00000000012. PMID 24724759. S2CID 35264961.
  10. ^ Jones G, Robertson L, Harrison R, Ridout C, Vasudevan P (August 2014). "Somatic mosaicism in ACVRL1 with transmission to several offspring affected with severe pulmonary arterial hypertension". American Journal of Medical Genetics. Part A. 164A (8): 2121–3. doi:10.1002/ajmg.a.36568. PMID 24753439. S2CID 5417225.
  11. ^ Kraehling JR, Chidlow JH, Rajagopal C, Sugiyama MG, Fowler JW, Lee MY, Zhang X, Ramírez CM, Park EJ, Tao B, Chen K, Kuruvilla L, Larriveé B, Folta-Stogniew E, Ola R, Rotllan N, Zhou W, Nagle MW, Herz J, Williams KJ, Eichmann A, Lee WL, Fernández-Hernando C, Sessa WC (November 2016). "Genome-wide RNAi screen reveals ALK1 mediates LDL uptake and transcytosis in endothelial cells". Nature Communications. 7: 13516. Bibcode:2016NatCo...713516K. doi:10.1038/ncomms13516. PMC 5121336. PMID 27869117.
  12. ^ Gupta S, Gill D, Pal SK, Agarwal N (2015). "Activin receptor inhibitors--dalantercept". Current Oncology Reports. 17 (4): 14. doi:10.1007/s11912-015-0441-5. PMID 25708802. S2CID 22676858.
  13. ^ Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA (July 2002). "Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542". Molecular Pharmacology. 62 (1): 58–64. doi:10.1124/mol.62.1.58. PMID 12065755. S2CID 792324.

Further reading

  • Attisano L, Cárcamo J, Ventura F, Weis FM, Massagué J, Wrana JL (November 1993). "Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors". Cell. 75 (4): 671–80. doi:10.1016/0092-8674(93)90488-C. PMID 8242742. S2CID 25408172.
  • Johnson DW, Berg JN, Gallione CJ, McAllister KA, Warner JP, Helmbold EA, Markel DS, Jackson CE, Porteous ME, Marchuk DA (August 1995). "A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12". Genome Research. 5 (1): 21–8. doi:10.1101/gr.5.1.21. PMID 8717052.
  • Panchenko MP, Williams MC, Brody JS, Yu Q (April 1996). "Type I receptor serine-threonine kinase preferentially expressed in pulmonary blood vessels". The American Journal of Physiology. 270 (4 Pt 1): L547-58. doi:10.1152/ajplung.1996.270.4.L547. PMID 8928814.
  • Berg JN, Gallione CJ, Stenzel TT, Johnson DW, Allen WP, Schwartz CE, Jackson CE, Porteous ME, Marchuk DA (July 1997). "The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2". American Journal of Human Genetics. 61 (1): 60–7. doi:10.1086/513903. PMC 1715857. PMID 9245985.
  • Stockwell BR, Schreiber SL (June 1998). "Probing the role of homomeric and heteromeric receptor interactions in TGF-beta signaling using small molecule dimerizers". Current Biology. 8 (13): 761–70. Bibcode:1998CBio....8..761S. doi:10.1016/S0960-9822(98)70299-4. PMID 9651680. S2CID 93779.
  • Lux A, Attisano L, Marchuk DA (April 1999). "Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1". The Journal of Biological Chemistry. 274 (15): 9984–92. doi:10.1074/jbc.274.15.9984. PMID 10187774.
  • Klaus DJ, Gallione CJ, Anthony K, Yeh EY, Yu J, Lux A, Johnson DW, Marchuk DA (2000). "Novel missense and frameshift mutations in the activin receptor-like kinase-1 gene in hereditary hemorrhagic telangiectasia. Mutations in brief no. 164. Online". Human Mutation. 12 (2): 137–138. doi:10.1002/(SICI)1098-1004(1998)12:2<137::AID-HUMU16>3.0.CO;2-J. PMID 10694922.
  • Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, Li E (March 2000). "Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis". Proceedings of the National Academy of Sciences of the United States of America. 97 (6): 2626–31. Bibcode:2000PNAS...97.2626O. doi:10.1073/pnas.97.6.2626. PMC 15979. PMID 10716993.
  • Abdalla SA, Pece-Barbara N, Vera S, Tapia E, Paez E, Bernabeu C, Letarte M (May 2000). "Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2". Human Molecular Genetics. 9 (8): 1227–37. doi:10.1093/hmg/9.8.1227. PMID 10767348.
  • Kjeldsen AD, Brusgaard K, Poulsen L, Kruse T, Rasmussen K, Green A, Vase P (February 2001). "Mutations in the ALK-1 gene and the phenotype of hereditary hemorrhagic telangiectasia in two large Danish families". American Journal of Medical Genetics. 98 (4): 298–302. doi:10.1002/1096-8628(20010201)98:4<298::AID-AJMG1093>3.0.CO;2-K. PMID 11170071.
  • Wurthner JU, Frank DB, Felici A, Green HM, Cao Z, Schneider MD, McNally JG, Lechleider RJ, Roberts AB (June 2001). "Transforming growth factor-beta receptor-associated protein 1 is a Smad4 chaperone". The Journal of Biological Chemistry. 276 (22): 19495–502. doi:10.1074/jbc.M006473200. PMID 11278302.
  • Parks WT, Frank DB, Huff C, Renfrew Haft C, Martin J, Meng X, de Caestecker MP, McNally JG, Reddi A, Taylor SI, Roberts AB, Wang T, Lechleider RJ (June 2001). "Sorting nexin 6, a novel SNX, interacts with the transforming growth factor-beta family of receptor serine-threonine kinases". The Journal of Biological Chemistry. 276 (22): 19332–9. doi:10.1074/jbc.M100606200. PMID 11279102.
  • Birkey Reffey S, Wurthner JU, Parks WT, Roberts AB, Duckett CS (July 2001). "X-linked inhibitor of apoptosis protein functions as a cofactor in transforming growth factor-beta signaling". The Journal of Biological Chemistry. 276 (28): 26542–9. doi:10.1074/jbc.M100331200. PMID 11356828.
  • Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, Simonneau G, Galie N, Loyd JE, Humbert M, Nichols WC, Morrell NW, Berg J, Manes A, McGaughran J, Pauciulo M, Wheeler L (August 2001). "Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia" (PDF). The New England Journal of Medicine. 345 (5): 325–34. doi:10.1056/NEJM200108023450503. hdl:2381/35988. PMID 11484689.
  • Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS (July 2002). "SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7". Molecular Pharmacology. 62 (1): 65–74. doi:10.1124/mol.62.1.65. PMID 12065756. S2CID 15185199.
  • Olivieri C, Mira E, Delù G, Pagella F, Zambelli A, Malvezzi L, Buscarini E, Danesino C (July 2002). "Identification of 13 new mutations in the ACVRL1 gene in a group of 52 unselected Italian patients affected by hereditary haemorrhagic telangiectasia". Journal of Medical Genetics. 39 (7): 39e–39. doi:10.1136/jmg.39.7.e39. PMC 1735165. PMID 12114496.
  • Mo J, Fang SJ, Chen W, Blobe GC (December 2002). "Regulation of ALK-1 signaling by the nuclear receptor LXRbeta". The Journal of Biological Chemistry. 277 (52): 50788–94. doi:10.1074/jbc.M210376200. PMID 12393874.
  • Lamouille S, Mallet C, Feige JJ, Bailly S (December 2002). "Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis". Blood. 100 (13): 4495–501. doi:10.1182/blood.V100.13.4495. PMID 12453878.
  • Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, Monnell TE, Solban N, Ucran JA, Pearsall RS, Underwood KW, Seehra J, Kumar R (February 2010). "ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth". Molecular Cancer Therapeutics. 9 (2): 379–88. doi:10.1158/1535-7163.MCT-09-0650. PMID 20124460.

External links

  • GeneReviews/NCBI/NIH/UW entry on Hereditary Hemorrhagic Telangiectasia
  • Human ACVRL1 genome location and ACVRL1 gene details page in the UCSC Genome Browser.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.


  • v
  • t
  • e
TGF beta superfamily of ligands
Ligand of ACVR or TGFBR
Ligand of BMPR
TGF beta receptors
(Activin, BMP, family)
TGFBR1:
TGFBR2:
TGFBR3:
Transducers/SMADLigand inhibitors
CoreceptorsOther
  • v
  • t
  • e
Non-specific serine/threonine protein kinases (EC 2.7.11.1)
Pyruvate dehydrogenase kinase (EC 2.7.11.2)
Dephospho-(reductase kinase) kinase (EC 2.7.11.3)
3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring) kinase (EC 2.7.11.4)
(isocitrate dehydrogenase (NADP+)) kinase (EC 2.7.11.5)
(tyrosine 3-monooxygenase) kinase (EC 2.7.11.6)
Myosin-heavy-chain kinase (EC 2.7.11.7)
Fas-activated serine/threonine kinase (EC 2.7.11.8)
Goodpasture-antigen-binding protein kinase (EC 2.7.11.9)
  • -
IκB kinase (EC 2.7.11.10)
cAMP-dependent protein kinase (EC 2.7.11.11)
cGMP-dependent protein kinase (EC 2.7.11.12)
Protein kinase C (EC 2.7.11.13)
Rhodopsin kinase (EC 2.7.11.14)
Beta adrenergic receptor kinase (EC 2.7.11.15)
G-protein coupled receptor kinases (EC 2.7.11.16)
Ca2+/calmodulin-dependent (EC 2.7.11.17)
Myosin light-chain kinase (EC 2.7.11.18)
Phosphorylase kinase (EC 2.7.11.19)
Elongation factor 2 kinase (EC 2.7.11.20)
Polo kinase (EC 2.7.11.21)
Serine/threonine-specific protein kinases (EC 2.7.11.21-EC 2.7.11.30)
Polo kinase (EC 2.7.11.21)
Cyclin-dependent kinase (EC 2.7.11.22)
(RNA-polymerase)-subunit kinase (EC 2.7.11.23)
Mitogen-activated protein kinase (EC 2.7.11.24)
MAP3K (EC 2.7.11.25)
Tau-protein kinase (EC 2.7.11.26)
(acetyl-CoA carboxylase) kinase (EC 2.7.11.27)
  • -
Tropomyosin kinase (EC 2.7.11.28)
  • -
Low-density-lipoprotein receptor kinase (EC 2.7.11.29)
  • -
Receptor protein serine/threonine kinase (EC 2.7.11.30)
MAP2K
  • v
  • t
  • e
TGFβ receptor superfamily modulators
Type I
ALK1 (ACVRL1)
  • Kinase inhibitors: K-02288
  • ML-347 (LDN-193719, VU0469381)
  • Other inhibitors: Disitertide
ALK2 (ACVR1A)
  • Kinase inhibitors: DMH-1
  • DMH-2
  • Dorsomorphin (BML-275)
  • K-02288
  • ML-347 (LDN-193719, VU0469381)
ALK3 (BMPR1A)
  • Kinase inhibitors: DMH-2
  • Dorsomorphin (BML-275)
  • K-02288
ALK4 (ACVR1B)
  • Kinase inhibitors: A 83-01
  • SB-431542
  • SB-505124
ALK5 (TGFβR1)
ALK6 (BMPR1B)
  • Kinase inhibitors: DMH-2
  • Dorsomorphin (BML-275)
  • K-02288
ALK7 (ACVR1C)
  • Antagonists: Lefty (1, 2)
  • Kinase inhibitors: A 83-01
  • SB-431542
  • SB-505124
Type II
TGFβR2
  • Kinase inhibitors: DMH-2
  • LY-364947
BMPR2
ACVR2A (ACVR2)
ACVR2B
  • Decoy receptors: Ramatercept
AMHR2 (AMHR)
Type III
TGFβR3 (β-glycan)
Unsorted
Portal:
  • icon Biology